pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CGTXCOGNITION THERAPEUTICS INC

$CGTX
Purchase, NY, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
zervimesine
Alzheimer's Disease

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodiescompletedn=130
  • —Expanded Access Program for CT1812 (Zervimesine)no longer available
  • phase2A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Diseaseactive not recruitingn=540
  • phase2A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.completedn=153
  • phase2Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).terminatedn=100
  • phase2Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGcompletedn=16
  • phase2Effect of CT1812 Treatment on Brain Synaptic Densitycompletedn=43
  • phase1Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjectscompletedn=8
🐶 Hiring Signal
No open roles indexed yet — view COGNITION THERAPEUTICS INC jobs →

News

  • CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s
    Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…
    biospace · 1d ago
identifiers
ticker
$CGTX
SEC CIK
0001455365
country
US
source
sec_tickers
top tags
Alzheimer's Disease1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 31m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?